Scott Kelly is a beast! A Rock Star. This is t

Quote:

---

Scott Kelly 12:45: We've been contacted by academic institutions interested in doing studies with LL. A researcher from a top university in Boston. CAR T research. CAR T not working as well against solid tumors as was hoped. For this study we will need to supply molecule only, (they will do trial). It is believed that the tumor micro environment is contributing to the lack of effectiveness of CAR T progress against solid tumors and we can control the tumor micro environment we may be able to enhance the effectiveness of CAR T Therapy.

We have been contacted by the department of neurological surgery at a major academic center in NYC. and they are planning to evaluate LL in glioblastoma multiforme which is a very aggressive brain tumor. Again, we will supply LL and they've expressed their interest that if successful, in this non-clinical model, that they would pay for a human trial.

In the study in the use of check point inhibitors, which is funded by CytoDyn, it may represent another potential opportunity in immunotherapy and is moving forward.

We have been in contact in London with the university and foundation to further evaluate the potential of LL as a treatment in Alzheimer's. Their interest is in the role of neuro inflammation. It is similar to the role of cancer where initially people did not believe that cancer had an inflammatory component. I think the same is true in a number of central nervous system disorders.

We are also considering the potential of LL acting as a long acting HIV prep agent in macaques. If successful, we are very excited about this. This has the potential to turn LL into a once every 3 month injection from once per week. This could be future of HIV treatment with Prep as a long acting injectable.

Possibility of a grant funded Phase 2 clinical trail in LL with HIV patients with NASH & NAFLD, where we supply LL, but do not pay for the trial.

Publications and presentations: We think that this will help with the credibility with CytoDyn. We have a poster presentation at American Association for Cancer Research on April 11, 2022. Dan Athens at Creative Microtech will be presenting. Dan Athens office submitted another poster presentation to another prominent oncology meeting this year.

We presented our mTNBC data at San Antonio breast conference in December, 2021 and we believe that was well received.

We are also processing 3 articles for publication in peer reviewed journals. 1st in on HIV monotherapy. 2) HIV multidrug resistance. 3) Covid 19 Long Haulers program.

Potential Partnerships: regarding NAFLD, looking both internationally and domestically; for 1) HIV Prep, we hope to use long acting LL, pending results of macaque study currently being done for once every 3 months injection, looking for partners in
2) Multidrug resistant HIV,
3) partners to complete the BLA submission with Inhouse BLA expertise, we are looking at partnerships in
4) HIV combo both internationally and domestically. partnerships with
5) existing agents that LL would be a great add on agent. and also with
6) HIV and
7) NASH looking to do a phase 2 clinical trial for obvious reasons.

For HIV patients, they have increased risk of NAFLD and NASH compared to general population.

Looking at combo therapy for NASH with LL and existing agent.

Market is growing at 58.64% annually. Expected to be $180.9billion by 2028.

In oncology, we are pursuing partnerships in unmet medical needs and quicker paths to approval. We do know that CCR5 is present on many tumors that are unmet medical needs as well as the tumor micro environment. Cancer immunotherapy is projected to be $277billion by 2030 growing by 12.6%.

Focus is on Partnerships for immunotherapy combination.

---